CD134 (OX40) Monoclonal Antibody (ACT35 (ACT-35)), FITC, eBioscience™, Invitrogen™

Description

• Description: The ACT35 monoclonal antibody reacts with human CD134, also known as OX-40
• A member of the TNF receptor superfamily, CD134/OX-40 is a 50 kDa type I membrane glycoprotein expressed by activated T lymphocytes
• The interaction of CD134 with OX-40L has been implicated in T cell-dependent humoral response, regulation of primary T cell expansion, survival of T cells, size of the memory T cell pool and regulation of tolerance in the CD4^+ T cell compartment
• Applications Reported: This ACT35 (ACT-35) antibody has been reported for use in flow cytometric analysis, immunohistology staining of frozen tissue sections, and immunohistology staining of paraffin embedded tissue sections
• Applications Tested: This ACT35 (ACT-35) antibody has been pre-titrated and tested by flow cytometric analysis of 3-day PHA-activated human normal human peripheral blood cells
• This can be used at 5 μL (0.5 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• OX40 is a protein receptor found on the surface of T cells, a type of white blood cell that plays a crucial role in the immune system
• When activated, OX40 promotes the proliferation and survival of T cells, leading to a stronger immune response against cancer cells and infectious agents
• OX40 agonists, which are drugs that activate OX40, have shown promising results in preclinical and clinical studies as a potential immunotherapy for cancer
• They can enhance the efficacy of other cancer treatments such as chemotherapy and checkpoint inhibitors, and may also have applications in autoimmune diseases and allergies.